CD274 and non-small cell lung carcinoma: Our results suggest that the addition of ICI to chemotherapy does not improve OS or PFS in patients with advanced NSCLC and a PD-L1 TPS of 1% to 49% who have liver metastases or have received prior antimicrobial therapy.